12:00 AM
 | 
Jun 23, 2014
 |  BioCentury  |  Emerging Company Profile

Dual: Multi-pronged attack

Dual developing PP2A activators to disrupt multiple cancer-associated pathways

Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers that are resistant to anti-androgens and chemotherapy.

Protein phosphatase 2 (PPP2CA; PP2A) is a serine/threonine phosphatase that is a tumor suppressor. It is down-regulated in various cancers.

D. Amy Trainor, a venture partner at BioMotiv LLC and project director for Dual, said the compounds could produce a robust therapeutic response in many types of cancer because they modulate multiple downstream targets and pathways, including androgen receptors, c-Myc (v-myc myelocytomatosis viral oncogene homolog; MYC), and the MAP kinase (MAPK) and protein kinase B (PKB; PKBA; AKT; AKT1) pathways.

She said lead compound DT-1154...

Read the full 653 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >